UNSPSC 51432705: Ramipril

This classification denotes an ace inhibitor with the molecular formula C23H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L35JN3I7SJ, chemically known as cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,6abeta))- but generally known as ramipril, which bears US NIH Compound Identifier 5362129. European Medicines Agency schedules Ramipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10248MIG.

UNSPSC 51432705 Ramipril is a Commodity code encompassing individual pharmaceutical products supplied to state and local health agencies, emergency services, and multi-state cooperative purchasing programs. State and local governments procure ramipril and other branded or generic medications through direct vendor solicitations, cooperative purchasing agreements, and RFPs that specify National Drug Codes, unit quantities, shelf-life requirements, expiration-date warranties, and delivery timelines. The issuing bodies span city fire rescue services (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating jurisdictions across multiple states). These agencies purchase pharmaceuticals for emergency medical services, state employee health plans, and distributed government healthcare facilities.

Recent opportunities show activity concentrated in Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving Oregon and other participating states. The City of Tampa's Purchasing Department issued IFB 26-P-00188 in April 2026, requesting advanced life support medications including epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and a two-year contract term effective July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and maintain cGMP and Drug Supply Chain Security Act compliance. The Tampa solicitation includes a Small Local Business Enterprise 5 percent bid discount and carries OSHA hazard communication and Section 508 accessibility documentation requirements.